NOD2 and Blau syndrome: In this study, we demonstrated that tofacitinib suppresses inflammatory cytokine production by inhibiting the expression of NOD2. We hope that tofacitinib will become a treatment option for Blau syndrome in the future and that the mechanism of granuloma formation will be elucidated.